<DOC>
	<DOC>NCT02358824</DOC>
	<brief_summary>A randomized, open-label, single-dose, four-period, two-way, crossover study,</brief_summary>
	<brief_title>CKD-828 (80/5mg) Pharmacokinetic Study</brief_title>
	<detailed_description>A randomized, open-label, single-dose, four-period, two-way, crossover study to compare the pharmacokinetics and safety CKD-828 (Fixed Dose Combination Tablet) to coadministration telmisartan and s-amlodipine in health volunteers.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>A healthy volunteer over 20 years old More than 50kg and within 20% of ideal body weight No any congenital or chronic diseases and medical symptom Appropriate for the study from examination(laboratory test, ECG etc.) within 4weeks prior to the first IP administration Signed the informed consent form prior to the study participation. History of relevant hypersensitivity against drug Clinical significant disease or medical history (ex. hepato/cholangio, cardio, endo, hemato, onco, CNS etc.) Active liver disease or abnormal laboratory result (AST or ALT or Total bilirubin &gt; 1.5*ULN) SBP &lt;90mmHg or SBP &gt;150mmHg DBP &lt;50mmHg or DBP &gt;100mmHg Creatinine clearance &lt;80mL/min A Disease(ex.inflammatory intestinal disease, gastric or duodenal ulcer ,hepatic disease history , gastrointestinal surgery except for appendectomy)that may influence on the absorption, distribution, metabolism and excretion of the drug The evidence of severe attack or acute disease or surgical intervention within 28 days prior to the first IP administration. A drug abuse or a heavy caffeine consumer (more than 5 cups per a day) or regular alcohol consumer(more than 21 units/week) or a heavy smoker(more than 10 cigarettes per a day) Taking ETC medicine or oriental medicine within 14days or Taking OTC medicine within 7days prior to the first IP administration Abnormal diet(Especially, grapefruit juice within 7 days prior to the first IP administration) that may influence on the absorption, distribution, metabolism and excretion of the drug</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>CKD-828</keyword>
	<keyword>Telmisartan</keyword>
	<keyword>S-amlodipine</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>